How Drug-Pricing Policy Hits Pharma

The Inflation Reduction Act gave CMS the authority to negotiate prices directly on a defined list of high-spend, no-generic-competition Medicare drugs. The negotiated price — the Maximum Fair Price — applies to Part D and Part B claims, and the law's schedule calls for the list to expand each year. For the initial cohort of drugs, the Maximum Fair Price ran 40-80% below prior list prices in early public disclosures, compressing the revenue line on products that had been among the most profitable in their issuers' portfolios.

The companies most exposed to this mechanism are large-cap, diversified biopharmas that derive a disproportionate share of revenue from a small number of aging blockbusters with no meaningful generic or biosimilar competition. Bristol-Myers Squibb (BMY), Merck (MRK), AstraZeneca (AZN), and Johnson & Johnson (JNJ) have all had drugs selected in early negotiation cycles. The key financial variable is not the negotiated price itself but the volume offset: if a lower price brings more patients onto a drug (because cost-sharing drops), some of the revenue loss is recovered. Drugs for which adherence is already high — where price is not limiting utilization — suffer the cleanest revenue cut.

The countervailing beneficiaries are companies with pipelines dominated by recently approved, patent-protected small-molecule drugs that are at least nine years from negotiation eligibility (thirteen years for biologics). Smaller-cap innovators and specialty biotechs with single-asset portfolios far from the negotiation window — think companies still in Phase 3 or just past first approval — are structurally insulated from this lever in the near term. Tracking signal: monitor CMS's annual drug-selection announcements (published each September under the IRA schedule) and cross-reference against each company's revenue concentration in its 10-K.

When a branded drug loses patent exclusivity, a generic can enter and, within months, capture 80-90% of volume at a fraction of the price. This is the patent cliff. It is perfectly predictable — patent expiration dates are public record — yet the market consistently underestimates the speed and completeness of generic erosion. For the losing brand, it is an earnings step-down; for the winning generic manufacturer, it is a one-time margin bonanza that erodes as additional generics pile in.

The generic entry windfall flows primarily to the first filer under the Hatch-Waxman 180-day exclusivity provision. The companies that most systematically capture this first-mover advantage include Teva Pharmaceutical (TEVA) and Viatris (VTRS), both of which maintain large patent-challenge pipelines. Hikma Pharmaceuticals (HKMY) is another major U.S.-market generic player. On the specialty generic and complex drug formulation side, Amneal Pharmaceuticals (AMRX) and Perrigo (PRGO) compete for erosion-resistant niches. The profitability of generic entry has itself declined over the past decade as the number of generic filers per molecule has grown, compressing prices faster. The durable edge now belongs to companies that can manufacture difficult-to-copy formulations — injectables, inhalants, controlled substances — where fewer competitors qualify.

For brand-name holders, the strategic response to an upcoming cliff is either a lifecycle management product (a reformulation or next-generation compound that can carry a new patent) or a legal settlement with the generic challenger that delays entry in exchange for a licensing fee. These settlement dates — when disclosed — are another signal to watch. Tracking signal: the FDA's Orange Book lists all patent expiration dates and paragraph IV certifications (generic patent challenges) for every approved drug. It is public, searchable, and updated continuously.

Biologics — drugs derived from living cells, including monoclonal antibodies, insulins, and protein therapies — follow a structurally similar dynamic to small molecules, but with a slower burn. The Biologics Price Competition and Innovation Act created an abbreviated approval pathway for biosimilars, but manufacturing complexity means fewer competitors qualify, the price discount off the reference biologic is shallower (typically 15-30% rather than 80-90%), and brand manufacturers can retain significant share through rebate contracting and prescriber loyalty.

The reference biologic manufacturers with the most exposure to biosimilar erosion are AbbVie (ABBV), whose Humira franchise faced the largest U.S. biosimilar wave in the country's history beginning in 2023, and Amgen (AMGN), which both faces biosimilar competition on legacy products and benefits from its own growing biosimilar pipeline. Pfizer (PFE) has aggressively built a biosimilar portfolio as a strategic hedge. On the pure-play biosimilar development side, Coherus BioSciences (CHRS) competes in ophthalmology and oncology biosimilars.

The policy dimension here is the FDA's interchangeability designation — a regulatory status that allows pharmacists to substitute a biosimilar for the reference biologic without physician sign-off. This designation dramatically accelerates biosimilar uptake by removing the prescriber friction that brand manufacturers rely on to hold share. Tracking signal: FDA's Purple Book (the biologic equivalent of the Orange Book) tracks all approved biosimilars and their interchangeability status. When an interchangeability designation is granted, the volume shift to the biosimilar accelerates — watch for it as a catalyst.

Medicare Part D is the outpatient prescription drug benefit, and its structure determines how rebates flow between drug manufacturers, pharmacy benefit managers (PBMs), and payers. The IRA's Part D redesign — which took full effect in 2025 — restructured the catastrophic coverage phase, capped out-of-pocket costs for Medicare beneficiaries, and shifted more liability onto manufacturers and PBMs in the high-cost tail of drug spending. This is a fundamental reordering of who absorbs the risk of high-cost patients.

PBMs are the intermediaries that sit between payers (insurers, Medicare plan sponsors) and pharmacies, negotiating drug prices and managing formularies. The three dominant PBMs — CVS Health's Caremark (CVS), Cigna's Express Scripts (CI), and UnitedHealth's Optum Rx (UNH) — are now explicitly exposed to greater cost-sharing in the catastrophic tier under the new structure. Their margin in Part D administration compresses when high-cost drug utilization rises. However, these same entities benefit from their ability to direct formulary placement, extracting higher rebates from manufacturers desperate to stay on preferred formulary tiers in an environment where volume is concentrated.

For drug manufacturers, the Part D redesign makes catastrophic-phase spending — previously backstopped largely by government reinsurance — a manufacturer liability. This disproportionately affects oncology drugs, rare-disease therapies, and specialty biologics where a single patient's annual drug cost can exceed $100,000. Tracking signal: in each company's 10-K and earnings calls, watch for disclosures on "gross-to-net" spreads (the gap between list price and net realized price after rebates and concessions). A widening gross-to-net is a sign that the company is paying more in rebates and price concessions to maintain formulary position — a structural margin headwind even when list prices hold steady.

The 340B Drug Pricing Program requires drug manufacturers to sell outpatient drugs to qualifying hospitals and clinics (those serving low-income populations) at a minimum discount — currently about 22-50% below the average manufacturer price for brand drugs. Originally a small-hospital safety-net program, 340B has grown into a roughly $50 billion annual program that now covers a significant share of drug purchases at large health systems. The tension is acute: manufacturers argue 340B hospitals are buying at deep discounts and then billing Medicare or commercial insurers at full price, capturing the spread as profit rather than passing it to patients.

Manufacturers have fought back by restricting 340B pricing to drugs dispensed at a qualifying entity's own in-house pharmacy, rather than through an extensive network of contract pharmacies. AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Eli Lilly (LLY), and Novartis (NVS) have all implemented contract pharmacy restrictions, triggering litigation with the Health Resources and Services Administration (HRSA). The courts have issued mixed rulings, and the final regulatory shape of 340B contract pharmacy policy remains contested.

For health systems that have built operating margins around 340B drug revenue — including large nonprofit hospital chains — any tightening of 340B eligibility or contract pharmacy restrictions is a direct earnings headwind. Publicly traded hospital operators such as HCA Healthcare (HCA) and Tenet Healthcare (THC) have 340B-eligible facilities and disclose 340B purchasing volumes. Tracking signal: HRSA's annual report on 340B program growth and manufacturer audit outcomes signals the direction of the administrative interpretations that govern who can access the discount. Litigation dockets in the D.C. Circuit on 340B contract pharmacy cases are the leading indicator.

Most developed-country governments set drug prices by reference to what other countries pay — a mechanism called international reference pricing or external reference pricing. The U.S. is the global price setter: because American list prices are higher than those in Germany, France, Japan, or the U.K., U.S. revenue subsidizes global R&D and margin. Any credible U.S. policy move toward tying domestic prices to an international index is therefore the most structurally disruptive pricing threat for U.S.-listed pharma.

The most concrete version of this threat has been "most favored nation" (MFN) pricing, which would require Medicare to pay no more for a drug than the lowest price paid by a peer country. Executive orders proposing MFN pricing have been issued and then delayed or rescinded, but the concept recurs across administrations. Even the threat — a credibly proposed rulemaking — tends to move large-cap pharma stocks, particularly those most exposed to Medicare Part B spending on physician-administered drugs. Amgen (AMGN), Regeneron (REGN), Gilead Sciences (GILD), and AbbVie (ABBV) have historically been cited in MFN analyses because of their heavy reliance on Medicare Part B-covered biologics.

The key variable is whether MFN applies to Part B (physician-administered drugs billed under the medical benefit, such as infused cancer drugs and ophthalmology injections) or Part D (the pharmacy benefit). Part B MFN is more immediately threatening to oncology-focused biotechs and large biologics companies; Part D MFN would impact the broader portfolio companies. Tracking signal: Federal Register notices and CMS proposed rulemaking comments are the authoritative source. When an MFN rulemaking comment period opens, count the congressional opposition letters — the volume of bipartisan resistance has historically predicted whether the rule survives to final implementation.

Most drug-pricing policy trades are not made on the day of announcement — they are made in the weeks before a final rule is published, when a savvy reader of the regulatory calendar can see the event coming. The two most actionable calendars are the Unified Regulatory Agenda (published twice a year by the White House Office of Information and Regulatory Affairs, detailing every pending federal rulemaking) and CMS's annual announcement cycle for Medicare drug negotiations, Part D bids, and reimbursement rate updates.

Earnings season is the second signal layer. When a CFO begins quantifying the revenue impact of a regulatory mechanism that management previously described only qualitatively, the market has typically not yet fully priced the magnitude. Specific language to flag: disclosures of the share of revenue subject to Medicare negotiation, updates on gross-to-net spread widening, commentary on contract pharmacy restriction litigation outcomes, and any quantification of biosimilar market share erosion rates. These are the moments where the policy-to-profit gap between announced mechanism and fully priced stock impact is widest.

Finally, watch FDA advisory committee calendars and PDUFA action dates for the beneficiary side of the equation. A drug that receives FDA approval with a broad label, a priority review voucher, or breakthrough therapy designation is a drug that may spend a decade outside the negotiation window while generating peak Medicare revenue. Companies with robust pipelines of recently approved drugs — Eli Lilly (LLY) in metabolic disease, Regeneron (REGN) in ophthalmology and immunology, Vertex Pharmaceuticals (VRTX) in cystic fibrosis — are structurally positioned to benefit from the same policy environment that squeezes older portfolios.